Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25490777 | 0.83 | MRGPRX4 (0.45) | HTTL3MBTL1ARKDM4EMRGPRX4 | |
| SCHEMBL6061341 | 0.81 | ACHE (0.47) | HTTL3MBTL1ARKDM4EMRGPRX4 | |
| SCHEMBL3151750 | 0.80 | AR (0.44) | HTTL3MBTL1ARKDM4EMRGPRX4 | |
| SCHEMBL922844 | 0.79 | TSHR (0.41) | HTTARACHECYP2C9SLC6A4 | |
| SCHEMBL28942882 | 0.78 | HTT (0.45) | HTTL3MBTL1ARKDM4EMRGPRX4 | |
| SCHEMBL8569226 | 0.77 | EZH2 (0.40) | HTTL3MBTL1KDM4E | |
| SCHEMBL7131209 | 0.76 | CYP2A6 (0.44) | HTTL3MBTL1ARKDM4EMRGPRX4 | |
| SCHEMBL920577 | 0.75 | GAA (0.41) | L3MBTL1ARACHESLC6A4HTR2A | |
| SCHEMBL7063003 | 0.75 | ESRRA (0.61) | L3MBTL1KDM4EMRGPRX4ESRRA | |
| SCHEMBL10001985 | 0.74 | AR (0.44) | ARACHEESRRACYP2C9SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030068347-A1 | Use of microbially encapsulated meterials in cosmetic end formulations | CIBA SPECIALTY CHEMICALS CORP. | 2003-04-10 | — | — | US | disclosed |
| EP-1246602-A2 | USE OF MICROBIALLY ENCAPSULATED MATERIALS IN COSMETIC END FORMULATIONS | Ciba SC Holding AG (CH) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051013-A2 | USE OF MICROBIALLY ENCAPSULATED MATERIALS IN COSMETIC END FORMULATIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030068347-A1 | Use of microbially encapsulated meterials in cosmetic end formulations | CUTA, MGLL, TMEM205 | HTT 1398/4885L3MBTL1 1744/4885AR 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.